T2	control 113 122	docetaxel
T1	intervention 38 64	navelbine and capecitabine
T3	eligibility 421 487	Patients with no prior chemotherapy for MBC and HER-2/neu negative
T5	total-participants 875 878	106
T6	total-participants 903 914	Ninety-four
T7	intervention-participants 1078 1087	Forty-one
T8	control-participants 1126 1128	29
T10	iv-bin-percent 1158 1160	56
T11	cv-bin-percent 1165 1168	71%
T12	outcome 1204 1230	median time to progression
T13	outcome 1235 1251	overall survival
T14	iv-cont-median 1257 1259	10
T15	iv-cont-median 1264 1273	35 months
T16	cv-cont-median 1287 1289	12
T17	cv-cont-median 1294 1303	37 months
T18	outcome 1347 1368	grade 3-4 neutropenia
T19	iv-bin-percent 1370 1373	10%
T20	outcome 1376 1390	grade 3 anemia
T21	iv-bin-percent 1392 1394	5%
T22	outcome 1404 1423	grade 3 neutropenia
T23	cv-bin-percent 1425 1427	6%
T24	outcome 1430 1444	grade 3 anemia
T25	cv-bin-percent 1446 1450	6.2%
T26	outcome 1457 1473	grade 2 alopecia
T27	cv-bin-percent 1475 1478	12%
T4	outcome 1148 1152	ORRs
T9	outcome 1535 1549	were tolerated
